García Mesa M, Arruzazabala Valmaña M L
National Center of Scientific Research, Department of Pharmacology and Toxicology, Havana, Cuba.
Allergol Immunopathol (Madr). 1989 Jan-Feb;17(1):33-4.
For many years, the mast cell has been considered the principal cell in bronchial asthma. However, there is some evidence to suggest that platelets might be involved in asthma. One of this evidence is the induction by platelet-activating factor or airway hyperreactivity and its inhibition by disodium cromoglycate and ketotifen. Since platelet aggregation is an index of platelet activation, we investigated the effect of these drugs on platelet aggregation induced by ADP, collagen and arachidonate in human platelet-rich plasma. The results obtained show that both drugs inhibit the effect of ADP and collagen. Ketotifen was also shown to inhibit the aggregation induced by arachidonate. The mechanism of the antiasthmatic action of these drugs is at present not clear. If platelet activation as it has been proposed, is involved in asthma, the antiaggregant effect of ketotifen and cromoglycate might be part of its beneficial effect in the treatment of asthma.
多年来,肥大细胞一直被认为是支气管哮喘中的主要细胞。然而,有一些证据表明血小板可能参与哮喘。其中一个证据是血小板活化因子可诱导气道高反应性,而色甘酸钠和酮替芬可抑制该反应。由于血小板聚集是血小板活化的一个指标,我们研究了这些药物对人富含血小板血浆中由二磷酸腺苷(ADP)、胶原和花生四烯酸诱导的血小板聚集的影响。所得结果表明,这两种药物均抑制ADP和胶原的作用。酮替芬也被证明可抑制花生四烯酸诱导的聚集。目前这些药物的抗哮喘作用机制尚不清楚。如果如所提出的那样血小板活化参与哮喘,那么酮替芬和色甘酸钠的抗聚集作用可能是其在哮喘治疗中有益作用的一部分。